<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03287024</url>
  </required_header>
  <id_info>
    <org_study_id>BNT002BeGrow</org_study_id>
    <nct_id>NCT03287024</nct_id>
  </id_info>
  <brief_title>BeGrow Study to Treat Pulmonary Artery (PA) Stenosis in Newborns and Infants</brief_title>
  <official_title>Prospective, Multicenter, Single-arm Study to Assess the Safety and Performance of the BeGrow Stent System in Newborns and Infants to Treat Pulmonary Artery Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bentley InnoMed GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LS medcap GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bentley InnoMed GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of the study is to assess safety and performance of the BeGrow Stent System for&#xD;
      newborns and infants in pulmonary artery stenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Bentley InnoMed &quot;BeGrow Stent System for Newborns and Infants&quot; is a stent delivery system&#xD;
      indicated for intraluminal placement in the pulmonary arteries of newborns and infants for&#xD;
      the treatment of Pulmonary Artery Stenosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, multi-centre, explorative single-arm study This open-label, non-randomized multi-centre study uses an &quot;umbrella protocol&quot; (Part A and Part B) designed to collect data for performance and safety as well as long-term safety data from pulmonary artery stenosis patients who are treated with the BeGrow stent system to treat the stenosis&#xD;
Part A: Safety and Performance (Implantation and Re-dilatation) Part B: Safety on Long-Term Follow-up</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vessel enlargement in mm</measure>
    <time_frame>after procedure and during follow ups up to 12 Months</time_frame>
    <description>Vessel enlargement will be measured in mm, directly before and after stent implantation by angiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events device and procedure related</measure>
    <time_frame>12 Months</time_frame>
    <description>Incidence of SAE</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Pulmonary Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>BeGrow Stent System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled subjects will receive the BeGrow Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BeGrow Stent System</intervention_name>
    <description>All enrolled subjects will undergo primary stenting of the target lesion by placement of the BeGrow Stent System</description>
    <arm_group_label>BeGrow Stent System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Single lesion(s) which can be treated with a 6 mm BeGrow stent (only one stent per&#xD;
             lesion allowed).&#xD;
&#xD;
          -  Pulmonary artery stenosis - patient must at least have one of the following diseases:&#xD;
&#xD;
               -  Haemodynamically relevant proximal or distal branch pulmonary artery stenosis&#xD;
                  with a reduction of the vessel diameter when the vessel/patient is large enough&#xD;
                  to accommodate a stent,&#xD;
&#xD;
               -  Haemodynamically relevant stenosis of the main pulmonary artery segment that&#xD;
                  results in elevation of the Right Ventricle (RV) pressure, provided that the&#xD;
                  stent definitely will not compromise a functioning pulmonary valve and will not&#xD;
                  impinge on the pulmonary artery bifurcation,&#xD;
&#xD;
               -  Any degree of stenosis in patients with single ventricle circulation&#xD;
&#xD;
               -  Critically ill postoperative cardiac patients when it has been determined that&#xD;
                  branch pulmonary artery stenosis is resulting in a definite haemodynamic&#xD;
                  compromise in a patient/vessel of any size, particularly if balloon dilatation is&#xD;
                  unsuccessful&#xD;
&#xD;
          -  Signed written informed consent (by parents/legal guardians)&#xD;
&#xD;
          -  Lesion can be accessed with a guide wire or balloon catheter&#xD;
&#xD;
          -  Age ≤ 24 months and weight ≥ 2 kg&#xD;
&#xD;
          -  Adequate stent length available&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The following lesions are excluded from treatment with BeGrow stent:&#xD;
&#xD;
               -  Shunt stenosis&#xD;
&#xD;
               -  Valvular and subvalvular pulmonary stenosis&#xD;
&#xD;
          -  Patients with known hypersensitivity to the stent material (L605 cobalt-chromium).&#xD;
&#xD;
          -  Patients with clinical or biological signs of infection.&#xD;
&#xD;
          -  Patients with active endocarditis.&#xD;
&#xD;
          -  Patients with known allergy to acetylsalicylic acid, other antiplatelet agents or&#xD;
             heparin.&#xD;
&#xD;
          -  Presence of other previously implanted stents in the same lesion or in close proximity&#xD;
             to stent (direct stent-stent contact).&#xD;
&#xD;
          -  Patients with known coagulation disorder.&#xD;
&#xD;
          -  Patients where direct stent-stent contact or overlapping cannot be avoided.&#xD;
&#xD;
          -  Patients where contact to the vessel wall over the entire stent length cannot be&#xD;
             ensured after dilatation (especially in short and thick lesions).&#xD;
&#xD;
          -  Patients where the BeGrow stent could protrude freely into adjacent vessels after&#xD;
             expansion/dilatation, including the pulmonary arterial bifurcation.&#xD;
&#xD;
          -  Implantation of the BeGrow stent in the pulmonary arterial bifurcation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Kretschmar, Prof.Dr.med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kinderspital Zürich, Pädiatrische Kardiologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universität Wien, AKH Wien, Abteilung für Pädiatrische Kardiologie</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital, Center for Pediatrics - Department of Cardiology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Serbia</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>September 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2017</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stenosis, Pulmonary Artery</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

